Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker Study of ATH434 in Advanced Multiple System Atrophy
NCT05864365Phase 2Completed
- Sponsor
- Alterity Therapeutics
- Start
- May 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ATH-434 in multiple system atrophy (MSA), sponsored by Alterity Therapeutics. Primary endpoint: Change in brain volume as measured by MRI at Week 52. Started May 2023; status: completed.
02
Drugs
ATH-434
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT05864365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05864365.